Vietnam is entering a significant period of investment in radiotherapy as a rising cancer burden, capacity constraints and the need to replace older equipment drive hospitals towards a new generation of precision cancer-treatment technologies.
Industry analysis suggests that Vietnam's radiotherapy market could be worth approximately US$60–80 million in 2025, with the potential to reach US$95–125 million by 2030.
These figures are an industry estimate rather than a separately published national market valuation, but the underlying evidence points to a market with substantial potential for equipment replacement, capacity expansion and technological upgrading.
The opportunity extends across linear accelerators, stereotactic radiosurgery, brachytherapy, treatment planning, oncology information systems, imaging, patient positioning, quality assurance and increasingly AI-enabled radiotherapy.
A growing requirement for cancer treatment
Vietnam records approximately 180,000 new cancer cases each year, creating increasing pressure on specialist hospitals and oncology centres.
Radiotherapy is an important component of cancer treatment, used either independently or alongside surgery, chemotherapy, immunotherapy and other systemic treatments.
The challenge for Vietnam is therefore not simply improving the sophistication of treatment. It is expanding the country's ability to provide radiotherapy to a growing patient population.
Evidence from major cancer centres illustrates the pressure.
K Hospital, Vietnam's leading specialist oncology hospital, receives more than 500,000 patient visits annually. Its radiotherapy equipment has been reported as operating for as long as 20–23 hours per day.
This combination of rising patient demand and heavily utilised equipment creates a compelling case for continued investment.
Vietnam has an established radiotherapy base — but much of it requires upgrading
A peer-reviewed national assessment of Vietnam's radiotherapy and nuclear-medicine infrastructure identified 82 linear accelerators.
Elekta accounted for 54 systems, Varian for 20, while eight older Siemens systems remained in operation.
More importantly from a market perspective, the study found that approximately 43% of Vietnam's LINACs were older models with limitations in delivering some advanced radiotherapy techniques.
That creates a significant replacement cycle.
Hospitals are not simply looking to add more treatment machines. They increasingly need equipment capable of delivering more precise treatments, processing patients faster and supporting techniques such as IMRT, VMAT, IGRT, SRS and SBRT.
Investment is already happening
The transition can already be seen across Vietnam.
K Hospital has continued to expand its radiotherapy capacity. By early 2026 it had nine linear accelerators and was adding next-generation systems capable of delivering advanced techniques including IMRT, VMAT, stereotactic radiosurgery and stereotactic body radiotherapy.
New systems can reduce some treatment sessions from around ten minutes to just two or three minutes, allowing hospitals to increase throughput while delivering radiation more precisely.
Investment is also moving beyond the country's largest national centres.
Phu Tho Provincial General Hospital has introduced an Elekta Versa HD system integrated with 4D CT simulation, while Can Tho Oncology Hospital introduced a Halcyon linear accelerator into its public healthcare infrastructure in 2026.
This geographical expansion matters commercially.
As advanced oncology moves beyond Hanoi and Ho Chi Minh City, the addressable market increasingly includes provincial hospitals and regional cancer centres.
Precision radiotherapy is becoming the new benchmark
Radiotherapy technology has changed substantially.
Traditional treatment techniques are increasingly being supplemented or replaced by systems capable of shaping radiation around complex tumours and adjusting treatment according to patient anatomy and tumour movement.
Intensity-Modulated Radiation Therapy (IMRT) enables the radiation dose to conform more closely to the tumour.
Volumetric Modulated Arc Therapy (VMAT) delivers highly modulated radiation as the treatment machine rotates around the patient.
Image-Guided Radiation Therapy (IGRT) uses imaging immediately before or during treatment to verify tumour location.
Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT) can deliver highly focused radiation doses to relatively small targets.
The commercial opportunity therefore extends beyond replacing older LINACs with equivalent equipment. Vietnam's treatment infrastructure is moving towards substantially more capable platforms.
Robotic radiosurgery opens another market
One indication of this technological shift came in 2025, when FV Hospital announced an investment of nearly VND200 billion in an Accuray CyberKnife S7 robotic radiosurgery system.
CyberKnife combines robotic treatment delivery with real-time image guidance and tumour tracking, enabling radiation to be delivered from multiple angles while responding to tumour movement.
Such technologies are particularly relevant to difficult-to-treat or surgically challenging tumours.
Advanced radiosurgery also highlights an important capacity issue.
Vietnam currently has limited dedicated Gamma Knife capacity relative to potential clinical demand. Research into the country's radiotherapy infrastructure suggests that expanding Gamma Knife and CyberKnife availability could become increasingly important as stereotactic treatment is adopted more widely.
Elekta and Varian dominate the installed LINAC base
Vietnam's current equipment landscape is concentrated around two major international suppliers.
Elekta represents approximately two-thirds of the country's installed LINAC base, with systems including Synergy, Infinity and Versa HD alongside Gamma Knife technology.
Varian, now part of Siemens Healthineers, accounts for most of the remaining modern LINAC installed base, including Clinac, TrueBeam, VitalBeam and Halcyon systems.
Accuray is strengthening its position in advanced robotic radiosurgery through CyberKnife.
This creates an established competitive market, but one where future opportunities extend considerably beyond the treatment machine itself.
The opportunity extends across the radiotherapy ecosystem
A modern radiotherapy department requires an extensive supporting technology infrastructure.
CT simulation is required to map tumours and plan treatment. Treatment-planning software determines how radiation should be delivered. Oncology information systems manage patient workflows and treatment records.
Patient-positioning and immobilisation systems help ensure that radiation is delivered accurately.
Dosimetry and quality-assurance equipment verify that the prescribed radiation dose is being delivered safely.
Software increasingly connects all these technologies.
As Vietnam upgrades its radiotherapy infrastructure, opportunities therefore extend across LINACs, Gamma Knife, CyberKnife, brachytherapy, CT simulation, treatment planning, oncology information systems, dosimetry, radiation measurement, positioning, immobilisation and quality assurance.
AI is entering radiation oncology
Artificial intelligence is also becoming increasingly relevant.
AI can support tumour and organ contouring, treatment planning, workflow optimisation and image analysis.
This has particular potential in healthcare systems facing high patient volumes and shortages of specialist personnel.
Rather than replacing radiation oncologists, medical physicists or radiographers, AI-enabled tools can automate repetitive elements of the treatment-planning process and help clinical teams work more efficiently.
The next generation of radiotherapy investment in Vietnam is therefore likely to combine increasingly sophisticated hardware with software, automation and AI.
Asia-Pacific provides a powerful growth backdrop
Vietnam's development is taking place within one of the world's fastest-growing radiation-oncology regions.
The Asia-Pacific radiation oncology market was worth approximately US$2.8 billion in 2025 and is forecast to exceed US$7.2 billion by 2033, representing annual growth of 12.6%.
External-beam radiotherapy remains the largest treatment segment, accounting for more than 80% of regional revenue in 2025.
The regional trajectory reflects many of the same factors visible in Vietnam: rising cancer incidence, increasing access to oncology treatment, government healthcare investment and adoption of more sophisticated treatment technologies.
A significant replacement and expansion opportunity
Vietnam's radiotherapy opportunity is therefore being driven by two markets simultaneously.
The first is capacity expansion: more patients require treatment and additional radiotherapy capacity is needed.
The second is technology replacement: a substantial proportion of the country's existing systems are older machines that cannot provide the full range of advanced treatments increasingly expected in modern radiation oncology.
Together, these dynamics could support an estimated market expansion from US$60–80 million in 2025 to approximately US$95–125 million by 2030.
For international manufacturers and technology providers, the opportunity extends across the entire cancer-treatment pathway — from simulation and treatment planning to radiation delivery, radiosurgery, brachytherapy, dosimetry, software, AI and quality assurance.
Vietnam does not simply need more radiotherapy equipment.
It needs greater treatment capacity, higher precision and a new generation of connected oncology infrastructure capable of bringing advanced cancer treatment to more patients across the country.